This is a non-core endpoint: only basic statistics are computed.
See these related core endpoints for full statistics:
Use of entacapone
PDMED_ENTACAPONE
No definition available.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
557745 |
1. Apply sex-specific ruleNone |
557745 |
2. Check conditionsNone |
557745 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
1 out of 7 registries used, show all original rules. |
360 |
4. Check minimum number of events
Min. number of events
3
|
360 |
5. Include endpointsNone |
360 |
6. Filter based on genotype QC (FinnGen only) |
311 |
Control definitions (FinnGen only)
Controls for this endpoint are individuals that are not cases.
Extra metadata
- First used in FinnGen datafreeze
- DF2
Similar endpoints
↥List of similar endpoints to
Use of entacapone
based on the number of shared cases.
Similar with more cases:
- Use of levodopa decarboxylase inhibitor
- Parkinson's disease
- Parkinson's disease, excluding more controls
- Parkinson's disease, including avohilmo
- Extrapyramidal and movement disorders
Similar with less cases:
None
Case counts by codes
↥Summary Statistics
↥-FinRegistry-
This endpoint is excluded from FinRegistry analyses (omitted endpoint).
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 311 | 111 | 200 |
| Unadjusted period prevalence (%) | 0.07 | 0.04 | 0.09 |
| Median age at first event (years) | 69.22 | 67.11 | 70.38 |
-FinnGen-
Age distribution of first events
-FinnGen-
Year distribution of first events
-FinnGen-
Cumulative Incidence Function
Not a core endpoint, no data to show.
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 319
- Matched controls
- 3190
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
N04BX02
ATC
entacapone; oral
+∞
307.7
319
*
N04BA02
ATC
levodopa and decarboxylase inhibitor; oral
+∞
307.7
319
87
G20
ICD-10 Finland
Parkinson disease
4854.7
307.7
316
62
N04BD01
ATC
selegiline; oral
391.1
307.7
227
20
110
Kela drug reimbursment
Parkinson's disease and comparable movement disrorders
5299.2
307.7
316
56
N04BA03
ATC
levodopa, decarboxylase inhibitor and COMT inhibitor; oral
727.8
307.7
222
10
N04BC05
ATC
pramipexole; oral
41.9
265.2
212
144
N87
ICPC
Parkinsonism
81.6
226.5
125
25
N04BB01
ATC
amantadine; oral
90.2
161.4
86
13
N04BC04
ATC
ropinirole; oral
293.9
118.6
114
6
N04BD02
ATC
rasagiline; oral
208.6
111.5
110
8
F02.39*G20
ICD-10 Finland
Dementia in Parkinson's disease without information on additional symptoms
259.3
107.9
105
6
193
Kela drug reimbursment
Rasagiline
269.1
97.4
95
5
N06DA03
ATC
rivastigmine; oral, transdermal
11.9
82.5
99
116
N05AH04
ATC
quetiapine; oral
8.6
80.6
149
295
N04AA02
ATC
biperiden; systemic
33.1
72.6
48
17
N03AE01
ATC
clonazepam; systemic
11.8
66.8
77
84
G02CB01
ATC
bromocriptine; systemic
169.1
54.8
56
*
N04BC02
ATC
pergolide; oral
309.3
52.8
52
*
N04BC09
ATC
rotigotine; transdermal
531.7
47.6
46
*
AAG20
NOMESCO Finland
Stereotactic intracranial implantation of electrodes
86.7
41.1
45
6
XA800
NOMESCO Finland
Neuropsychological investigation
12.2
39.0
41
38
N04BC06
ATC
cabergoline; oral
221.3
38.7
39
*
R25.1
ICD-10 Finland
Tremor, unspecified
12.6
37.8
39
35
AEA50
NOMESCO Finland
Adjustment of implanted neurostimulator
88.7
35.7
39
5
WYA30
NOMESCO Finland
Treatment of a patient needing special arrangements
6.2
30.7
59
113
AEA00
NOMESCO Finland
Replacement of impulse generator of stimulation device in the nervous system
45.8
27.4
33
8
Z2445
NOMESCO Finland
Psychologist
10.2
25.7
30
32
A06AD11
ATC
lactulose; oral
3.5
24.9
121
471
307
Kela drug reimbursment
Tacrine, donepezil, rivastigmine, galantamine and other major and expensive drugs used to treat Alzheimer's disease
4.8
23.9
61
149
3320A
ICD-9 Finland
Parkinson's disease, Paralysis agitans
90.2
23.0
25
*
N04BC01
ATC
bromocriptine; oral
+∞
22.1
21
*
N04BX01
ATC
tolcapone; oral
+∞
17.9
17
*
H02AA02
ATC
fludrocortisone; oral
14.5
16.8
28
21
JDB10
NOMESCO Finland
Percutaneous gastrostomy
19.2
16.8
25
14
G21.9
ICD-10 Finland
Secondary parkinsonism, unspecified
24.9
15.3
21
9
N04BX04
ATC
opicapone; oral
84.1
14.7
16
*
F02.39
ICD-10 Finland
Dementia in Parkinson's disease without information on additional symptoms
84.1
14.7
16
*
N39.0
ICD-10 Finland
Urinary tract infection, site not specified
2.9
14.7
87
366
R1250
NOMESCO Finland
Evaluation of functional capability
6.9
13.8
22
34
W01
ICD-10 Finland
Fall on same level from slipping, tripping and stumbling
2.4
13.6
154
884
S01.0
ICD-10 Finland
Open wound of scalp
3.4
13.5
55
185
N05BA04
ATC
oxazepam; oral
2.5
13.0
114
580
J69.0
ICD-10 Finland
Pneumonitis due to food and vomit
6.1
12.9
23
40
I95.1
ICD-10 Finland
Orthostatic hypotension
3.9
12.3
39
111
N06AX11
ATC
mirtazapine; oral
2.3
11.8
126
694
G25.9
ICD-10 Finland
Extrapyramidal and movement disorder, unspecified
14.3
11.6
19
14
N19
ICPC
Speech disorder
14.3
11.6
19
14
C07AA05
ATC
propranolol; systemic
2.8
11.5
67
276
XKD06
NOMESCO Finland
Physiologic investigation of micturition
5.0
11.4
25
53
G04BD12
ATC
mirabegron; oral
2.8
11.3
66
273
N06AB04
ATC
citalopram; systemic
2.5
11.1
90
437
SPAT1231
SPAT
Assessment of adjustments needed in living environment
5.7
11.0
21
39
ZXM20
NOMESCO Finland
Intraoperative use of computerised tomography
13.5
10.8
18
14
SPAT1224
SPAT
Implementation of speech therapy rehabilitation plan
14.9
10.6
17
12
R47.1
ICD-10 Finland
Dysarthria and anarthria
11.8
10.2
18
16
SPAT1229
SPAT
Assessment of need for aid
3.0
10.0
47
172
N05AH02
ATC
clozapine; systemic
18.2
9.5
14
8
NA3AD
NOMESCO Finland
Lumbar spine and sacrum CT examination
5.1
9.4
20
41
R13
ICD-10 Finland
Dysphagia
3.1
9.4
42
149
SPAT1215
SPAT
Assessment of need for medical rehabilitation
4.5
9.3
23
54
R4130
NOMESCO Finland
Speech therapy
5.0
9.2
20
42
N30.0
ICD-10 Finland
Acute cystitis
2.5
9.1
64
288
N06AB10
ATC
escitalopram; oral
2.6
9.1
61
269
S72.0
ICD-10 Finland
Fracture of neck of femur
3.1
9.0
40
141
Z02.4
ICD-10 Finland
Examination for driving licence
0.3
8.9
28
761
R53
ICD-10 Finland
Malaise and fatigue
2.1
8.8
106
600
JX1LA
NOMESCO Finland
Kinetic X-ray of alimentary tract with pictures
51.4
8.7
10
*
XF606
NOMESCO Finland
Ortostatic test
28.4
8.5
11
*
ZXE30
NOMESCO Finland
More than five and less than seven hours
4.0
8.4
24
63
N04AA01
ATC
trihexyphenidyl; oral
+∞
8.4
8
*
Z00.4
ICD-10 Finland
General psychiatric examination, not elsewhere classified
3.9
8.4
25
68
R29.8
ICD-10 Finland
Other and unspecified symptoms and signs involving the nervous and musculoskeletal systems
3.0
8.2
38
137
I10
ICD-10 Finland
Essential (primary) hypertension
0.5
8.0
129
1830
N05CD07
ATC
temazepam; oral
2.3
8.0
71
354
K59.09
ICD-10 Finland
Constipation, unspecified
2.9
7.9
40
152
N30.9
ICD-10 Finland
Cystitis, unspecified
3.1
7.9
34
118
AA1AD
NOMESCO Finland
CT of head and brain
2.0
7.8
123
763
JDW98
NOMESCO Finland
Other transluminal endoscopic operation on stomach or duodenum
10.4
7.6
14
14
WX006
NOMESCO Finland
Intravenous sedation or analgesia without general anesthesia
3.4
7.6
28
88
N10
ICD-10 Finland
Acute tubulo-interstitial nephritis
2.2
7.5
72
371
N02AE01
ATC
buprenorphine; parenteral, sublingual, transdermal
2.2
7.4
75
395
WX700
NOMESCO Finland
Respiratory and circulatory monitoring
2.3
7.4
64
316
N04BC07
ATC
apomorphine; parenteral
+∞
7.3
7
*
AAW01
NOMESCO Finland
Implantation of intracranial stimulation device
+∞
7.3
7
*
C10AA07
ATC
rosuvastatin; oral
0.3
7.3
27
686
C10AX09
ATC
ezetimibe; oral
0.2
7.2
8
351
N29
ICPC
Neurological sympt/complt other
8.2
7.2
15
19
C10AA05
ATC
atorvastatin; oral
0.5
7.1
64
1120
AA1BD
NOMESCO Finland
Extensive CT of head and brain
4.5
7.0
17
39
N03AX12
ATC
[U] gabapentin; oral
2.3
6.8
58
284
D21
ICPC
Swallowing problem
6.7
6.7
16
25
A28
ICPC
Limited function/disability NOS
2.0
6.6
93
550
N06AX03
ATC
mianserin; oral
3.1
6.6
27
91
AA1BG
NOMESCO Finland
Standard MRI examination of brain with high intensity magnet
2.8
6.5
33
126
N05BA06
ATC
lorazepam; systemic, sublingual
3.0
6.5
29
103
F0230, G20,
ICD-10 Finland
71.2
6.4
7
*
YX8AD
NOMESCO Finland
Stereotactic CT examination for dose design of radiotherapy
27.3
6.3
8
*
N39.4
ICD-10 Finland
Other specified urinary incontinence
2.6
6.2
38
160
ZXE10
NOMESCO Finland
More than one and less than three hours
1.8
6.1
124
823
M48.0
ICD-10 Finland
Spinal stenosis
2.1
6.0
60
312
A10BK03
ATC
empagliflozin; oral
0.1
6.0
*
223
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
134
2058
0.40
14.40
3.8
5.6
4.20
4.36
mmol/l
1.46
122
1855
134
2048
0.40
13.98
3.7
5.4
1.37
1.42
mmol/l
0.79
119
1826
126
1975
0.40
13.96
3.3
4.7
1.17
1.25
mmol/l
0.92
112
1748
148
2114
0.44
11.62
4.0
6.4
2.39
2.48
mmol/l
0.84
132
1889
145
2080
0.44
11.35
5.7
7.5
39.23
40.91
mmol/mol
1.53
136
1894
38
888
0.35
8.94
3.6
4.1
3.97
10.13
mg/mmol
2.21
27
575
155
2099
0.49
8.85
4.1
5.8
5.88
6.17
mmol/l
2.13
136
1862
173
2245
0.50
8.38
8.8
13.1
14.15
23.56
u/l
18.51
155
2154
40
832
0.41
6.86
1.6
2.0
1.18
1.30
mmol/l
0.64
30
656
86
1334
0.51
6.46
2.5
3.4
63.04
55.65
u/l
0.17
80
1221
162
2070
0.56
6.09
22.8
20.4
86.30
71.39
ml/min/173m2
21.60
154
1937
189
2310
0.55
5.99
33.4
30.4
244.77
236.00
e9/l
1.20
184
2247
189
2310
0.55
5.99
33.1
30.4
4.29
4.37
e12/l
1.32
182
2235
156
1995
0.57
5.60
4.4
5.3
1.92
2.05
mu/l
0.63
144
1756
128
1720
0.57
5.47
3.3
4.6
11.94
15.16
mm/h
1.91
120
1564
70
1083
0.55
4.75
5.2
5.9
5.14
3.70
ug/l
0.28
64
947
36
662
0.49
4.13
3.6
3.0
302.10
366.17
umol/l
3.23
30
549
70
1040
0.58
3.91
3.0
3.5
1473.83
1985.04
ng/l
0.49
61
893
18
68
2.75
3.63
3.4
4.5
27.17
34.15
mg/l
0.45
13
51
149
1836
0.65
3.61
5.3
8.6
84.52
82.38
u/l
0.20
135
1720
186
2186
0.64
3.59
24.0
20.6
29.95
27.54
mg/l
0.42
167
1884
103
1368
0.64
3.49
4.4
6.7
10.99
12.24
umol/l
0.92
96
1293
130
1626
0.66
3.21
3.4
4.2
14.56
15.11
pmol/l
1.53
114
1420
64
434
1.59
2.67
3.9
3.4
2.20
1.43
e6/l
0.33
29
228
6
11
5.53
2.55
1.3
1.8
—
—
—
0
0
105
1330
0.69
2.54
9.6
9.5
4.61
4.37
e9/l
0.34
82
1147
66
458
1.56
2.49
4.0
3.2
0.85
1.05
e6/l
0.34
31
247
77
1023
0.67
2.36
2.6
3.1
143.46
149.28
ug/l
0.06
67
925
90
1151
0.70
2.21
4.8
4.7
37.20
45.68
ng/l
0.26
70
933
9
207
0.42
2.16
1.1
1.4
—
—
—
0
0
7
175
0.39
2.10
1.1
1.4
—
—
—
0
0
64
862
0.68
2.06
4.6
4.9
16.00
22.25
%
2.66
26
461
17
313
0.52
1.92
2.6
4.5
2.59
47.94
ug/l
—
10
269
14
275
0.49
1.92
2.3
2.6
3.79
6.67
ug/l
1.60
14
240
0
51
0.00
1.90
0.0
1.2
—
33.29
—
0
44
45
625
0.67
1.67
3.0
3.4
0.66
0.89
ug/l
2.01
31
436
11
220
0.48
1.61
3.1
3.3
5.02
5.15
kpa
0.20
11
212
10
197
0.49
1.42
3.8
3.2
123.80
127.79
g/l
—
10
190
118
1376
0.77
1.40
5.5
7.1
1.21
1.21
mmol/l
0.47
105
1159
0
39
0.00
1.34
0.0
4.4
—
—
—
0
0
0
40
0.00
1.33
0.0
1.4
—
—
—
0
0
6
132
0.44
1.31
2.5
3.2
84.50
1713.62
u/ml
—
6
113
40
535
0.71
1.21
1.5
1.7
1.21
1.52
mg/l
0.47
34
439
47
611
0.73
1.19
2.1
1.9
334.03
35366295.45
pmol/l
0.74
40
492
113
965
1.26
1.19
4.2
3.6
—
—
—
0
0
136
1537
0.80
1.18
5.2
5.4
6.27
6.89
mmol/l
5.76
131
1475
0
33
0.00
1.17
0.0
1.5
—
—
—
0
0
0
33
0.00
1.17
0.0
1.5
—
—
—
0
0
0
33
0.00
1.17
0.0
1.5
—
—
—
0
0
17
268
0.61
1.15
2.9
2.9
3.82
4.27
kpa
0.60
17
258
62
769
0.76
1.15
2.4
2.3
3.27
3.17
mg/l
0.07
51
647
48
368
1.36
1.10
2.4
2.0
—
—
—
0
0
21
311
0.65
1.09
2.6
3.7
5.99
5.78
kpa
0.33
21
300
88
1037
0.79
1.08
2.2
2.5
67.69
78.74
nmol/l
3.59
77
895
91
772
1.25
1.00
4.7
3.5
0.28
0.45
e6/l
1.02
65
581
49
385
1.32
0.97
2.4
1.9
—
—
—
0
0
0
32
0.00
0.95
0.0
1.5
—
—
—
0
0
0
32
0.00
0.95
0.0
1.5
—
—
—
0
0
0
32
0.00
0.95
0.0
1.5
—
—
—
0
0
68
563
1.26
0.92
4.8
4.7
1.02
1.02
kg/l
1.26
52
390
125
1395
0.83
0.88
11.9
18.4
1.28
1.37
inr
1.29
107
1189
78
909
0.81
0.85
3.3
3.3
2.32
2.34
mmol/l
1.02
73
817
6
112
0.53
0.85
3.7
2.9
—
—
—
0
0
0
25
0.00
0.79
0.0
1.8
—
—
—
0
0
0
25
0.00
0.79
0.0
1.7
—
—
—
0
0
0
25
0.00
0.79
0.0
1.7
—
—
—
0
0
0
25
0.00
0.79
0.0
1.7
—
—
—
0
0
25
183
1.40
0.78
2.0
1.8
—
—
—
0
0
0
28
0.00
0.76
0.0
3.0
—
846.04
—
0
28
0
28
0.00
0.76
0.0
1.7
—
—
—
0
0
112
1246
0.84
0.73
4.7
6.4
1.20
1.21
mmol/l
0.25
105
1136
5
26
1.94
0.71
1.2
1.6
—
—
—
0
0
5
26
1.94
0.71
2.4
1.8
0.60
2.25
u/field
—
5
12
109
1209
0.85
0.68
4.8
4.7
35.24
34.53
g/l
0.71
102
1116
13
188
0.68
0.64
1.5
2.3
10.95
12.78
nmol/l
0.28
13
168
0
20
0.00
0.60
0.0
1.2
—
—
—
0
0
0
20
0.00
0.60
0.0
1.3
—
—
—
0
0
35
427
0.80
0.59
4.5
6.4
105.66
104.10
mmol/l
0.82
35
427
0
23
0.00
0.58
0.0
1.0
—
533.27
—
0
15
0
23
0.00
0.58
0.0
1.1
—
41.30
—
0
14
23
294
0.77
0.56
6.8
8.7
—
—
—
0
0
6
99
0.60
0.52
1.0
1.3
—
—
—
0
0
51
588
0.84
0.50
2.3
3.1
2.46
2.46
mmol/l
0.11
45
525
7
110
0.63
0.49
2.1
3.2
4.20
4.25
pmol/l
—
7
96
5
85
0.58
0.46
1.2
1.3
—
—
—
0
0
38
323
1.20
0.44
5.4
3.9
—
—
—
0
0
40
465
0.84
0.44
2.3
3.0
0.83
0.82
mmol/l
0.24
40
435
15
195
0.76
0.43
4.1
2.7
76.57
57.04
ml/min/173m2
—
7
85
17
216
0.78
0.41
1.4
1.5
—
—
—
0
0
0
15
0.00
0.41
0.0
1.1
—
—
—
0
0
0
16
0.00
0.41
0.0
1.3
—
—
—
0
0
0
16
0.00
0.41
0.0
1.3
—
—
—
0
0
0
17
0.00
0.41
0.0
1.1
—
—
—
0
0
0
17
0.00
0.41
0.0
1.1
—
—
—
0
0
0
18
0.00
0.40
0.0
1.0
—
—
—
0
0
0
19
0.00
0.39
0.0
1.0
—
—
—
0
0
111
1186
0.90
0.36
2.5
2.3
82.23
94.61
pmol/l
3.39
84
627
82
755
1.12
0.34
5.1
4.5
0.00
0.01
estimate
0.50
30
261
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
6
90
0.66
0.33
1.8
2.2
0.96
0.39
iu/ml
—
6
47
7
55
1.28
0.30
1.3
1.4
—
—
—
0
0
5
39
1.29
0.23
1.2
1.5
—
—
—
0
0
5
39
1.29
0.23
1.6
1.5
—
—
—
0
0
0
11
0.00
0.21
0.0
1.0
—
—
—
0
0
0
11
0.00
0.21
0.0
1.9
—
—
—
0
0
0
11
0.00
0.21
0.0
1.0
—
—
—
0
0
0
11
0.00
0.21
0.0
1.6
—
24.01
—
0
11
0
11
0.00
0.21
0.0
1.9
—
—
—
0
0
0
11
0.00
0.21
0.0
4.4
—
76.27
—
0
11
0
10
0.00
0.21
0.0
1.2
—
—
—
0
0
0
10
0.00
0.21
0.0
1.0
—
42.20
—
0
10
0
12
0.00
0.21
0.0
1.2
—
33.90
—
0
7
0
12
0.00
0.21
0.0
1.2
—
—
—
0
0
0
12
0.00
0.21
0.0
1.0
—
—
—
0
0
0
12
0.00
0.21
0.0
1.2
—
—
—
0
0
0
12
0.00
0.21
0.0
1.8
—
—
—
0
0
0
13
0.00
0.21
0.0
1.8
—
—
—
0
0
0
13
0.00
0.21
0.0
1.8
—
—
—
0
0
0
13
0.00
0.21
0.0
1.8
—
—
—
0
0
0
13
0.00
0.21
0.0
1.8
—
—
—
0
0
76
716
1.08
0.21
6.5
4.0
0.00
0.14
estimate
0.71
31
234
0
14
0.00
0.20
0.0
1.1
—
—
—
0
0
0
14
0.00
0.20
0.0
1.1
—
—
—
0
0
0
14
0.00
0.20
0.0
1.0
—
—
—
0
0
7
59
1.19
0.18
1.6
1.4
—
—
—
0
0
7
59
1.19
0.18
1.6
1.4
—
—
—
0
0
51
546
0.92
0.18
3.4
4.1
92.35
264.75
ng/l
1.18
40
484
103
988
1.06
0.17
6.3
4.6
0.00
0.05
estimate
1.43
27
247
5
69
0.72
0.17
1.6
1.5
—
—
—
0
0
5
70
0.71
0.17
1.2
1.2
—
—
—
0
0
5
70
0.71
0.17
1.2
1.2
—
—
—
0
0
87
831
1.06
0.16
2.1
1.8
20.44
20.51
nmol/l
0.01
75
676
18
158
1.15
0.16
1.3
1.4
—
—
—
0
0
8
69
1.16
0.16
1.0
1.3
—
—
—
0
0
6
78
0.76
0.15
1.5
1.6
—
—
—
0
0
6
80
0.75
0.15
1.2
1.6
—
—
—
0
0
169
1649
1.05
0.15
7.7
5.3
9273.40
2076.70
e6/l
0.64
15
43
56
593
0.93
0.15
1.7
1.8
1246.34
1198.60
nmol/l
0.13
47
439
7
90
0.77
0.14
1.1
1.0
—
—
—
0
0
54
519
1.05
0.08
2.6
1.9
—
—
—
0
0
5
61
0.82
0.08
1.6
1.5
—
—
—
0
0
60
621
0.96
0.08
1.9
2.5
—
—
—
0
0
8
77
1.04
0.07
2.0
1.5
—
—
—
0
0
25
238
1.05
0.05
3.8
2.7
0.24
0.61
e6/l
0.45
25
229
125
1267
0.98
0.05
6.2
4.4
0.00
0.00
estimate
-0.00
28
295
38
367
1.04
0.05
5.0
7.0
2.17
1.34
mmol/l
0.62
29
307
114
1124
1.02
0.04
2.5
2.9
—
—
estimate
—
0
0
128
1296
0.98
0.04
6.2
4.5
0.00
1.07
estimate
0.51
30
283
99
1004
0.98
0.04
3.1
2.4
—
—
—
0
0
128
1287
0.99
0.01
6.1
4.5
0.00
5.29
estimate
0.50
31
307
16
162
0.99
0.00
1.1
1.4
—
—
—
0
0
5
50
1.00
0.00
1.6
1.7
—
—
—
0
0
5
50
1.00
0.00
1.8
1.3
24.20
175.58
e6/l
—
5
40
5
50
1.00
0.00
1.6
1.6
—
—
—
0
0
(40770918) von Willebrand factor (vWf).activity actual/normal in Platelet poor plasma by Immunoassay
0
6
0.00
-0.00
0.0
3.7
—
125.00
—
0
6
0
5
0.00
-0.00
0.0
8.8
—
10.78
—
0
5
0
5
0.00
-0.00
0.0
1.6
—
12.40
—
0
5
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
5
57
0.88
-0.00
1.6
1.6
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
1695.00
—
0
5
0
9
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.7
—
85.57
—
0
7
0
9
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.7
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
1.14
—
0
5
0
7
0.00
-0.00
0.0
1.1
—
—
—
0
0
9
90
1.00
-0.00
2.1
1.7
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.0
—
10.34
—
0
8
0
9
0.00
-0.00
0.0
1.6
—
1066.67
—
0
9
Mortality – FinRegistry
↥This endpoint is excluded from FinRegistry analyses (omitted endpoint).
Relationships between endpoints
↥Index endpoint: PDMED_ENTACAPONE – Use of entacapone
GWS hits: -
This endpoint is excluded from FinRegistry analyses (omitted endpoint).